Meeder Advisory Services Inc. Sells 181 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Meeder Advisory Services Inc. cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,084 shares of the medical research company’s stock after selling 181 shares during the quarter. Meeder Advisory Services Inc.’s holdings in Thermo Fisher Scientific were worth $3,685,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of TMO. Norges Bank purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $3,149,754,000. Proficio Capital Partners LLC raised its stake in Thermo Fisher Scientific by 68,617.0% during the fourth quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company’s stock valued at $396,810,000 after buying an additional 761,649 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $377,901,000. Lindsell Train Ltd bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $211,858,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Thermo Fisher Scientific by 15.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,810,128 shares of the medical research company’s stock worth $1,461,913,000 after purchasing an additional 366,191 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares of the company’s stock, valued at $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $482.51 on Wednesday. The stock has a 50-day simple moving average of $538.56 and a two-hundred day simple moving average of $550.11. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a 52-week low of $481.21 and a 52-week high of $627.88. The firm has a market capitalization of $182.03 billion, a PE ratio of 29.19, a P/E/G ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.36%. The ex-dividend date is Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is presently 10.41%.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent analyst reports. Raymond James reaffirmed an “outperform” rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Scotiabank upped their price objective on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research report on Monday, February 3rd. Citigroup reduced their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Wells Fargo & Company increased their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Finally, UBS Group boosted their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $653.23.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.